埃托多拉克单剂量代谢概况阐述:健康志愿者的药理动力学和不良事件
Karen Sánchez-Luquez1, Anne Michelli Reis Silveira1,2, Salvador Sánchez-Vinces1
1Health Sciences Postgraduate Program, São Francisco University-USF, Bragança Paulista 12916-900, SP, Brazil.
Pharmaceuticals (Basel, Switzerland)
|January 25, 2025
概括
这项研究分析了etodolac在健康志愿者的代谢作用. 关键发现将阿拉基酸代谢物与药物药理动力学和其他途径与临床参数联系起来,有助于个性化医疗.
科学领域:
- 药理学 药理学是指药理学的学科.
- 代谢学 代谢学 代谢学
- 生物化学 生物化学
背景情况:
- 埃托多拉克是一种非类固醇抗炎药物 (NSAID).
- 了解其代谢特征对于预测药物反应和安全至关重要.
- 个体的代谢变化可以影响药物的疗效和不良事件.
研究的目的:
- 为了研究etodolac在健康志愿者的代谢概况.
- 为了确定与etodolac的药理动力学,临床参数和安全性相关的生物标志物和代谢途径.
- 探索剂前和剂后代谢变异之间的关系.
主要方法:
- 对37名健康志愿者进行单剂量埃托多拉克 (500毫克) 的治疗.
- 使用双重质谱法进行药物动力学分析.
- 通过液态染色体质谱法 (LC-MS/MS) 在剂前和剂后样本上进行代谢分析.
- 网络分析用于数据解释.
主要成果:
- 在新陈代谢概况和etodolac的药理动力学之间发现的相关性.
- 阿拉基酸代谢物 (前列腺素,白血) 与埃托多拉克的药理动力学有关.
- 胆固醇生物合成中的代谢物,胆汁盐, рибофлавин和视网酸通路与血液学和肝功能参数相关.
- 观察到的相关性与报告的罕见不良事件如血液学和肝功能变化一致.
结论:
- 确定了与埃托多拉克的作用和潜在副作用相关的特定代谢物和途径.
- 在服用埃托多拉克剂量之前和之后的代谢概况提供了对药物反应的见解.
- 个体的新陈代谢概况对于优化埃托多拉克治疗和最大限度地减少不良事件很重要.
相关概念视频
Time Course of Drug Effect
1.9K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
1.9K
Drug Metabolism: Phase I Reactions
3.0K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
3.0K
Drug Elimination: Non-Renal Routes
2.3K
The liver plays a pivotal role in eliminating drugs and their metabolites, primarily through a process known as biliary excretion. This process involves the hepatocytes, the primary cells in the liver that generate bile. A range of transporters actively expels polar drugs or hydrophilic drug metabolites into the bile, which transports the drugs and metabolites into the small intestine. From here, they are eventually expelled from the body through feces. In some instances, the original drug or a...
2.3K
Pharmacokinetics: Overview
5.4K
Pharmacokinetics is a scientific discipline that focuses on the journey of a drug within the body, encompassing four key stages: absorption, distribution, metabolism, and elimination. The first stage, absorption, involves the drug's transfer into the bloodstream. Several factors dictate the extent and speed of this process. For example, the liver often metabolizes oral drugs before they reach systemic circulation, leading to only partial absorption. In contrast, intravenous (IV)...
5.4K
Drug Metabolism: Phase II Reactions
3.6K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.6K
Dose-Response Relationship: Potency and Efficacy
4.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
4.2K


